HENLIUS(02696)
30.500-3.350-9.90%
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
- Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101
Reuters · 03-20 14:12
- Shanghai Henlius Biotech Says Orphan-Drug Designation Granted By US FDAShanghai Henlius Biotech Says Orphan-Drug Designation Granted By US FDA
Reuters · 03-19
- Shanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDAShanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDA
THOMSON REUTERS · 03-19
- BRIEF-UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEXBRIEF-UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEX
Reuters · 02-19
- UBS Group's Long Position in H Shares of Shanghai Henlius Biotech Increases to 7.55% on Feb 13 From 5.43% - HKEXUBS Group's Long Position in H Shares of Shanghai Henlius Biotech Increases to 7.55% on Feb 13 From 5.43% - HKEX
THOMSON REUTERS · 02-19
- FDA Approves Shanghai Henlius Biotech's Investigational New Drug Application for Anti-Neurodegenerative Disease DrugFDA Approves Shanghai Henlius Biotech's Investigational New Drug Application for Anti-Neurodegenerative Disease Drug
MT Newswires Live · 02-10
- Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in ChinaHenlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China
MT Newswires Live · 02-10
- BRIEF-Shanghai Henlius Biotech's New Drug Application Of Innovative Small Molecular Hlx99 Approved By U.S. FDABRIEF-Shanghai Henlius Biotech's New Drug Application Of Innovative Small Molecular Hlx99 Approved By U.S. FDA
Reuters · 02-10
- Shanghai Henlius Biotech Inc - Co's New Drug Application of Innovative Small Molecular Hlx99 ("Hlx99") Was Approved by U.S. FDAShanghai Henlius Biotech Inc - Co's New Drug Application of Innovative Small Molecular Hlx99 ("Hlx99") Was Approved by U.S. FDA
THOMSON REUTERS · 02-10
- Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma DrugHenlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug
MT Newswires Live · 02-07
- Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma DrugStock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug
Stock Track · 02-07
- BUZZ-Henlius soars on deal with India's Dr. Reddy's Labs for myeloma drugBUZZ-Henlius soars on deal with India's Dr. Reddy's Labs for myeloma drug
Reuters · 02-07
- Henlius: Co and DR. Reddy's Ink Licensing Deal for Hlx15 Expansion in Europe and U.S.Henlius: Co and DR. Reddy's Ink Licensing Deal for Hlx15 Expansion in Europe and U.S.
THOMSON REUTERS · 02-06
- BRIEF-Shanghai Henlius Biotech Says License Agreement With Dr. Reddy's For HLX15BRIEF-Shanghai Henlius Biotech Says License Agreement With Dr. Reddy's For HLX15
Reuters · 02-06
- Shanghai Henlius Biotech Inc - DR. Reddy's Shall Pay Company US$33 MlnShanghai Henlius Biotech Inc - DR. Reddy's Shall Pay Company US$33 Mln
THOMSON REUTERS · 02-06
- Shanghai Henlius Biotech's Anti-Lung Cancer Injection Gets European Commission's ApprovalShanghai Henlius Biotech's Anti-Lung Cancer Injection Gets European Commission's Approval
MT Newswires Live · 02-06
- BRIEF-Shanghai Henlius Biotech Says European Commission Approved Serplulimab InjectionBRIEF-Shanghai Henlius Biotech Says European Commission Approved Serplulimab Injection
Reuters · 02-05
- BRIEF-Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)BRIEF-Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Reuters · 02-05
- Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Es-Sclc)Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Es-Sclc)
THOMSON REUTERS · 02-05
- Shanghai Henlius Biotech Inc - European Commission Approved Serplulimab Injection in Combination With ChemotherapyShanghai Henlius Biotech Inc - European Commission Approved Serplulimab Injection in Combination With Chemotherapy
THOMSON REUTERS · 02-05
High
33.800
Open
33.800
Volume%
2.46
Low
29.350
Close
33.850
T/O Rate
2.56%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial